Xufen Yu

发表

Macrocyclic Drugs and Synthetic Methodologies toward Macrocycles

Dianqing Sun, Dianqing Sun, Xufen Yu, 2013, Molecules.

Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.

Jian Jin, Xufen Yu, Kwang-Su Park, 2022, Journal of medicinal chemistry.

Design, Synthesis and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).

Samuel T. Slocum, Xi-Ping Huang, T. Kenakin, 2019, Journal of medicinal chemistry.

Discovery of First-in-class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.

Xian Chen, Ling Xie, E. Guccione, 2020, Journal of medicinal chemistry.

Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic

Stephanie D. Byrum, Aaron J. Storey, G. Wang, 2022, Oncogene.

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.

Xian Chen, Ling Xie, R. Parsons, 2021, Journal of medicinal chemistry.

Proteolysis Targeting Chimaeras Induce the Degradation of Epidermal Growth Factor Receptor in Lung Cancer

Y. Xiong, Jian Jin, Xufen Yu, 2020 .

Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism

D. Tuveson, E. White, W. Zong, 2019, Cell reports.

Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic

Stephanie D. Byrum, Aaron J. Storey, G. Wang, 2022, Oncogene.

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.

Xian Chen, Ling Xie, H. Kaniskan, 2022, ACS pharmacology & translational science.

A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation

G. Wang, H. Earp, Ling Cai, 2022, bioRxiv.

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.

Xian Chen, Ling Xie, R. Parsons, 2022, Journal of medicinal chemistry.

Facile Cu(OTf)2-catalyzed preparation of 9-tosylaminofluorene derivatives from o-arylated N-tosylbenzaldimines

Xufen Yu, Xiyan Lu, 2011 .

Cationic Palladium Complex‐Catalyzed Diastereoselective Tandem Annulation of 2‐Iminoarylboronic Acids with Substituted Alkynes: Enantioselective Synthesis of Aminoindene Derivatives by Double Asymmetric Induction

Xufen Yu, Xiyan Lu, 2011 .

Synthesis, evaluation, and CoMFA study of fluoroquinophenoxazine derivatives as bacterial topoisomerase IA inhibitors.

Y. Tse‐Dinh, Dianqing Sun, Xufen Yu, 2017, European journal of medicinal chemistry.

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-molecule Degraders.

Xian Chen, Ling Xie, Y. Xiong, 2020, Journal of medicinal chemistry.

Synthesis of 2-arylindole derivatives and evaluation as nitric oxide synthase and NFκB inhibitors.

J. Pezzuto, T. Kondratyuk, Dianqing Sun, 2012, Organic & biomolecular chemistry.

Efficient Synthesis of 9‐Tosylaminofluorene Derivatives by Boron Trifluoride Etherate‐Catalyzed Aza‐Friedel–Crafts Reaction of in situ Generated N‐Tosylbenzaldimines

Xufen Yu, Xiyan Lu, 2011 .

Cationic palladium complex catalyzed diastereo- and enantioselective tandem annulation of 2-formylarylboronic acids with allenoates.

Xufen Yu, Xiyan Lu, 2009, Organic letters.

Cationic palladium-catalyzed [5 + 2] annulation of 2-acylmethoxyarylboronic acids and allenoates: synthesis of 1-benzoxepine derivatives.

Xufen Yu, Xiyan Lu, 2011, The Journal of organic chemistry.

Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader

G. Wang, Anqi Ma, Ling Cai, 2023, Oncogene.

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

R. Roeder, G. Wang, Anqi Ma, 2022, Nature Cell Biology.

ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism

Aaron J. Storey, D. Zheng, G. Wang, 2021, Nature Communications.

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

R. Roeder, G. Wang, W. Pi, 2022, Nature Cell Biology.

Inhibition of EZH2 primes the cardiac gene activation via removal of epigenetic repression during human direct cardiac reprogramming

Jianyi(Jay) Zhang, Jian Jin, L. Qian, 2021, Stem cell research.

AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B.

Xian Chen, Ling Xie, Rui Qiao, 2021, Cancer discovery.

UV-induced reduction in Polycomb repression promotes epidermal pigmentation.

D. Zheng, Jose M. Silva, J. D'Orazio, 2021, Developmental cell.

Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery.

Kyle V. Butler, J. Khan, B. Gryder, 2019, Nature Biotechnology.

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia

J. Qi, R. Roeder, G. Wang, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Designing Functionally Selective Non-Catechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.

Xi-Ping Huang, W. Wetsel, M. Caron, 2019, ACS chemical neuroscience.

Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation

Y. Dou, D. Nguyen, T. Westbrook, 2022, bioRxiv.

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models

Laura E. Herring, G. Wang, R. Jain, 2021, Science Translational Medicine.

Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D1 Receptor Agonists.

Xi-Ping Huang, B. Roth, M. Caron, 2019, Journal of medicinal chemistry.

Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization

K. Saxena, S. Knapp, Andreas Krämer, 2023, bioRxiv.

Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.

Y. Xiong, Jian Jin, Xufen Yu, 2022, Journal of medicinal chemistry.

Chemically induced degradation of epigenetic targets.

H. Kaniskan, Xufen Yu, Jian Jin, 2023, Chemical Society reviews.

Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.

Arun K. Ghosh, I. Weber, H. Mitsuya, 2015, Journal of medicinal chemistry.

TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors.

Xian Chen, Ling Xie, Wenyi Wei, 2022, Journal of the American Chemical Society.

Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.

J. Pezzuto, T. Kondratyuk, Dianqing Sun, 2017, Bioorganic & medicinal chemistry letters.

Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics

Hongjun Song, J. Cook, Xian Chen, 2020, bioRxiv.

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma

Mary E. Duffy, J. Llovet, E. Guccione, 2023, Nature Cancer.

Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound

P. Tiwari, A. Uhlemann, F. Leng, 2018, bioRxiv.

Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.

Yonghui Wang, Xufen Yu, Zhendong Chen, 2023, European journal of medicinal chemistry.

Targeting G9a translational mechanism of SARS-CoV-2 pathogenesis for multifaceted therapeutics of COVID-19 and its sequalae

Xuping Xie, Xufen Yu, Feng Zhang, 2024, bioRxiv.

Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.

Laura E. Herring, Ling Xie, Ling Cai, 2023, Journal of medicinal chemistry.